July 21 (Reuters) - Mesoblast Ltd MSB.AX :
* FDA ADVISORY COMMITTEE SETS REVIEW DATE FOR MESOBLAST'S REMESTEMCEL-L IN PEDIATRIC STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE
* MESOBLAST LTD - RYONCIL IS UNDER PRIORITY REVIEW BY FDA WITH ACTION DATE OF SEPTEMBER 30, UNDER PRESCRIPTION DRUG USER FEE ACT
* MESOBLAST - FDA ADVISORY COMMITTEE SETS REVIEW DATE OF AUG 13 FOR CO'S REMESTEMCEL-L IN PEDIATRIC STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE